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Summary: A soluble somatostatin binding factor was detected in cell-free extracts from chicken pancreas. For
binding measurements Tyr1-somatostatin was radio-labeled with 125I by the lactoperoxidase technique. Specific
radioactivity of about 18.5 MBq/nmol was achieved. Maximal total binding is approximately 0.17 ( ) in the presence
of 30 mg/1 pancreatic protein. The specific binding is 0.10 and is suppressed by addition of 1 mg/1 synthetic cold
cyclic somatostatin.
The dose-response curve of synthetic cyclic somatostatin is in the range of 0.6—600 nmol/1. Ca2"1" and reduced thiol-
reagents inhibit the specific binding. Insulin, glucagon and corticotropin show a low, and luliberin and reduced
somatostatin a high cross-reactivity. Molecular weight was estimated by gel filtration and the specific binding mole-
cule was eluted at a Kav = 0.2 on an Ultrogel® (AcA 54) column. This corresponds toMT 40 000. Electrophoretic
properties of the binding complex and semipurification by polyacrylamide disc gel electrophoresis: relative mobility
of the 12SI-Tyr-somatostatin binding complex is about 0.6. Relative mobilities of binding-protein fractions are 0.71
and 0.74. Highest relative specific binding was detected in the (100 000 g) cytosol fractions. Binding with cell-free
extracts from the splenic lobe area was 4^fold higher than that from other parts of the chicken pancreas.
Somatostatin-Bindungsfaktor aus Hühnerpankreas
Zusammenfassung: Ein löslicher Somatostatin-Bindungsfaktor wird in zellfreien Extrakten von Hühnerpankreas
nachgewiesen. Zur Messung der Bindung wird Tyr1-Somatostatin mit 125I radiomarkiert (Lactoperoxidase-Technik).
Eine spezifische Radioaktivität von 18,5 MBq/nmol wird erreicht. Die maximale totale Bindung beträgt annähernd
0,17 ( ) in Gegenwart von 30 mg/1 pankreatischem Protein. Die spezifische Bindung beträgt 0,10 und ist nach
Zugabe von l mg/1 synthetischem cyclischen Somatostatin verdrängbar. Die dose-response-Kurve von synthetischem
cyclischen Somatostatin liegt im Bereich 0,6—600 nmol/1. Ca2* und reduziertes Thiolreagenz hemmt die Bindung,
Insulin, Glucagon und Corticotropin (ACTH) zeigen eine schwache und Luliberin (LH-RH) sowie reduziertes Somato-
statin (SRIF) weisen eine hohe Kreuzreaktivität auf. Das Molekulargewicht wird mittels Gelfiltration geschätzt: das
spezifische Bindungsprotein wird bei einem Kav = 0,2 mit einer Ultrogel® (AcA 54>Säule eluiert. MT = 40 000.
Elektrophoretische Eigenschaften des Bindungskomplexes und des mittels Polyacrylamidgel-Elektrophorese ange-
reicherten Bindungsfaktors: Die relative Mobilität des [125^Ty 1]Somatostatin-Bindungskom lexes beträgt etwa
0,6; die der Bindungsproteinfraktionen 0,71 und 0,74. Die höchste relative spezifische Bindung wird in der 100 000 g
Cytoplasmafraktion gefunden. Die Bindung mit zellfreien Extrakten aus dem Bereich des Milzlappens ist 4-mal höher
als in anderen Bereichen des Hühner-Pankreas.
Introduction Furthermore, a multitude of inhibiting effects of
The tetradecapeptide somatostatin, which was originally somatostatin are well documented (for review: see I.e.
identified in hypothalamic extracts, is distributed (7)). However, little is known about the mechanism of
throughout the central nervous system, and is also found action of somatostatin at the cellular and subcellular
in the gastrointestinal tract arid in the pancreas (1-6). level. In this context it may be of importance that a
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specific binding protein has been demonstrated in
different organs (8).
It is also known that somatostatin inhibits secretion of
glucagon and insulin in the islet cells of the pancreas (9).
In addition to endocrine functions, a paracrine and/or
local effect of somatostatin-producing pancreatic D-cells
(10) on the glucagon- and insulin-secreting neighbouring
cells can be assumed. Immunochemical investigations
show that high concentrations of somatostatin are
located in the chicken pancreas dark islet cell areas,
where large amounts of D-cells can be found (11). The
possibility, however, that somatostatin is secreted in
connection with binding proteins has so far received
little attention. Since the paracrine actions of somato-
statin might be influenced by binding proteins, e.g.
carriers and receptors, the biochemical characterization
of those proteins is of importance.
We have now been able to demonstrate that a specific
somatostatin binding factor occurs in dark islet cell
areas of the chicken pancreas.
This paper characterizes the soluble somatostatin binding
factor.
Binding assay and separation of bound (B) and free (F)
somatostatin
Routinely the following assay was performed (tab. 1): The
binding assays were performed with the crude supernatants
(cell-free extracts) 600 g> 15 000 g, and 100 000 g. After 2 h
incubation time at 4 °C, the reaction was stopped by addition
of dextran-coated charcoal The mixtures were agitated for
15 min using a "whirl-mix" and then centrifuged.
Radioactivity of supernatants and charcoal fractions were
measured in an automatic gamma counter (Packard 5166) and
the B/T-values (total radioactivity, t = B + F) were calculated.
Tab. 1. Routine procedure for the for the binding assay.
940 ìÉ-960 ì\ 50 mmol/1 tris (hydroxymethyl)-amino-
methane, 10 mmol/1 EDTA, 1 g/1 gelatin
pH 8.0
20 ìÀ synthetic cyclic somatostatin* (1 Mg)
20 ìÀ [12SI-Tyr1lsomatostatin (200 Bq)
20 ìÀ extract
10-30 mg/1 protein
h To each second tube cold synthetic somatostatin was added.
Specific binding (B/T) was estimated corresponding to the




Cyclic somatostatin, cyclic Tyr1 -somatostatin, and linear somato-
statin were purchased from Serono (Freiburg). Lactoperoxidase
(EC 1.11.1.7) and reference proteins for the molecular weight
determinations were obtained from Boehringer (Mannheim);
aprotinin (Trasylol®), Bayer (Leverkusen); insulin, glucagon,
luliberin (LH-RH), thyroliberin (TRH), Hoechst (Frankfurt);
corticotropin, porcine (ACTH), Ferring (Kiel); AcA 54-® "Urtro-
gel", LKB (Sweden), and "Sephadex" gels, Pharmacia (Frank-
furt); Ion-exchange resin (Dowex 1 X 10) and charcoal Norit A,
Serva (Heidelberg) coated with 15% dextran T 40 obtained from
Pharmacia (Frankfurt); Na125I, Amersham-Buchler (Braun-
schweig); bovine serum albumin, Bearing (Marburg). All other
chemicals (p.a. grade) were purchased from Merck (Darmstadt)
or Boehringer (Mannheim) unless otherwise specified in the text
Since somatostatin readily absorbs to glass surfaces, incubations
were carried out in "Minisorb" tubes from NUNC (Denmark).
Radiolabeling
Labeling of Tyr1-somatostatin with 125I was performed according
to the lactoperoxidase/H2O2-technique (12). Dowex 1 X 10 anion
exchange resin and Sephadex G-25 absorption chromatography
were used for further purification of the labeled hormone (13).
Gel-filtration
Gel chromatography was done with Ultrogel AcA 54. Phosphate
buffer 0.01 mol/i pH 7.5, was applied for elution and the
absorption at 280 nm measured continuously unless described
otherwise.
Pofyacrylamide disc gel electrophoresis
Disc-electrophoresis was performed as described by Davis (15),
pH 8.9-75 g/L A flat gel (3 mm) apparatus from Desaga (Heidel-
berg) was used. Volumes of 20-60 ìÀ (1-2 g/l protein) of the
binding fractions were carefully pipetted into prepolymerized
pockets of the spacer gel The samples were mixed with 5 ìÀ
1 mol/1 sucrose to avoid rapid diffusion into the electrode buffer.
Electrophoresis was started with a voltage of 250 V for the first
5 mirij then the potential was stepwise elevated up to 500 V.
The electric current decreased slightly during a separation time
of 2 h. The flat gel was cut longitudinally and incubated in a fixa-
tive stain solution: Coomassie Brilliant Blue R 250 (2.5 g/l) in
125 g/l trichlproacetic acid, or Amido-Black 10 B in 70 g/1
acetic acid. The stained gels were washed and scanned, at 580
nm, or 620 nm, respectively, in a gel scanner from Zeiss. The
longitudinal gels were sliced (2 mm pieces) and radioactivity
(I25j) was measured in an automatic gamma counter (Packard
5166).
Preparation of cell-free extracts
Adult domestic fowls (Warren-sex-sal-link) were decapitated and
bled without anaesthesia. The pancreas was separated from the
surrounding tissue. About 0.15 g of the splenic lobe area were
cut, weighed and washed with 1 ml 10 mmol/1 tris (hydroxy-
methyl)-aminomethane/Ha buffer, pH 8.0, 100-500 KIE
aprotinin. The pancreatic tissue was homogenized in a twenty-
fold volume of the same buffer by treatment (20 strokes,
1600 rpm) with a glass-Teflon-homogenatoi at 4 °C. Fractions
were frozen and stored below -20 6C Different areas of the
pancreas were worked up in the same manner. Protein was
measured according to the method of Bradford (14), Biorad
(M nchen).
Results
Interaction ï/[125/·7>/·1 ]somatostatin with binding
factor from chicken pancreas
Binding of [12SI-Tyr1] somatostatin to fractions of cell-
free extracts of the chicken pancreas could be demon-
strated. Maximal binding was founid with "retarded"
[12SI-Tyr1] somatostatin fractions of Sephadex G-25
adsorption chromatography (fig. 1). Specific radio-
activity of 18.5 MBq/nmpl was achieved.
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Fig. 1. Adsorption chromatography (Sephadex G-25) elution
pattern of [ 125I-Tyr1 ]somatostatin.
The reaction mixture (1 ml = 2 MBq), prepared by the
lactoperoxidase/H2O2-techmque, as described in Materials
Methods, was applied to a column (1.5 X 30 cm) of Sepha-
dex G-25. The column was eluted with 1 g/1 gelatin in
0.05-0.2 mmol/1 ammonium acetate pH 6.7 within 2 h
at room temperature. 2.5 ml fractions were collected and
50 ìÀ aliquots were measured in a scintillation counter
(Packard 5166), V0 indicates the dextran blue 2000 and
Vt the Na125I fraction.
•—r-· eluted radioactivity
ï ï the total binding B/T of each second fraction
(5 ìÀ) incubated with cell-free extract of the
chicken pancreas (P3) 20 h at 4 °C.
The amounts of bound radioactivity were determined as
described in Materials and Methods. Each point gives the
mean of the duplicate values. Maximal total binding is
achieved at the retarded fraction No. 34.
Under standard incubation conditions, maximal binding
is about 0.17 (bound/total = B/T), and unspecific binding
(samples without binding factor) ranges from 0.05-0.09.
Weir et al. (11) found a higher amount of somatostatin-
like immuriofeactivity in the splenic lobe than in other
areas of the chicken pancreas. Iri figure 2 a scheme of
chicken pancreas is demonstrated.
A schematic cutting out of the islets of Langerhans is
shown in figure 2b and the local regulatory connections
are shov/n in figure 2 c. The interactions of [U5I-Tyr ]-
somatostatin were measured with homogenates and/or
cell-free extracts from different areas of the chicken
pancreas. Binding of somatostatin is 4-fold in the splenic
lobe area (P3) compared with inferior parts of the
chicken pancreas (P2 and Pr) (fig. 2 a).
Bovine serum albumin as well binds [125I-Tyr1]somato-
statin, as shown in figure 3. However, in this case, an in-
crease of the binding can only be achieved at higher






Fig. 2. Schematic drawings showing
a) chicken pancreas with the splenic lobe area (circle)
where high amounts of dark islet cells are located,
i*¥> »>.
^3 »
b) neighbouring islet cells producing glucagon (A),
insulin (B), and somatostatin (D);
c) the regulation triangle, where somatostatin (D) inhibits
glucagon (A) and insulin (B) secretion (negative feed-
back), which in total is responsible for glucose homeo-
stasis. The somatostatin binding factor is linked to
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Fig. 3. Binding B/T of [I25l-Tyr11 somatostatin with cell-free
extracts (100 000 g) of the splenic lobe area of chicken
pancreas (Pa;Ä Ä), bovine serum albumin (* A),
and ovalbumin (· ·). Different concentrations of
the proteins were incubated under standard conditions
and bound and free somatostatin were separated applying
the charcoal technique (see Materials and Methods). Each
point gives the mean of the duplicate values.
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Specificity and dose-response of binding
Addition of an excess (1 mg/1) of cold synthetic cyclic
somatostatin to the incubation medium results in a
displacement of 125I-labeled Tyr1-somatostatin. The
relative amount of displaceable radioactivity by synthetic
cyclic somatostatin is defined as specific binding. Maximal
values achieved are about 0.10 (^).
This maximal binding is reversible as it could be demon-
strated by coincubation and preincubation experiments
with [I2sl-Tyr1]somatostatin. However, when cold cyclic
somatostatin is preincubated for about 30 min the
specific binding (as defined in this paper) increases to
0.11-0.14 (|). It was found that 0.01-0.04 (|) of this
binding is irreversible.
Usually coincubation of labeled and unlabeled ligands
was performed (tab. 1).
The pH-optimum is at pH 8, and equilibrium is reached
after 20 h incubation time at 4 °C. For routine determi-
nation, a 2 h reaction time has been employed since
0.90 of the maxima] binding is achieved after this incuba-
tion time.
Table 2 summarizes specific binding values dependent
on Ca2+ and thiol-reagents, including linear somato-
statin, which contains free thiol-groups. Thus, it has
been demonstrated that EDTA is necessary for optimal
binding, and Ca2* ions are inhibitory.
The binding is inhibited by compounds containing
reducing thiolgroups. This effect is observed not only
in the presence of reducing agents such as dithiothreitol,
but also with reduced glutathione (GSH) and reduced
somatostatin (linear form). Oxidized glutathione
(GSSG) does not inhibit the specific binding.
The dose-dependent inhibition of the specific binding
between [125I-Tyr1]somatostatin and cell-free extract
of the splenic lobe area (P3) by synthetic cyclic somato-
statin is illustrated in figure 4.
50%-displacement occurs in the region of 15 nmol/1.
Cyclic somatostatin and linear somatostatin show
parallel dose-response curves, but the linear peptide
has a 10-fold weaker (50%-)displacement.
Tab. 2. Influence of Ca2+ and thiol reagents on the binding of
radioiodinated Tyr ̂ somatostatin to a cell-free extract



























Fig. 4. Dose-response curves of the protein binding assay for
cyclic somatostatin and cross-reactivity of other peptides.
Cell-free extracts of "P3" (30 Mg protein) were assayed
with [^I-Tyr1] somatostatin (200 Bq from fraction 34,
G-25 chromatography) in the presence of cyclic somato-
statin (o o), linear somatostatin (* A incubations
under N2-atmosphere), luliberin (o a), corticotropin
(v v), glucagon (· ·), insulin (· ·), thyroliberin
(Ä Ä), each 0.6-6000 nmol/1. Maximal specific binding
was 0.07 (B/T).
The incubation conditions are described in Materials and
Methods. The concentrations of the added peptides are
plotted logarithmically on the abscissa. B/T values were
calculated and the blank value (sample without binding
protein) is subtracted. Each point gives the mean of
duplicates.
Cross-reactivity also can be observed with luliberin
(LH-RH), which causes 50^displacement at 500 nmol/1.
Thyroliberin (TRH), insulin, glucagon, and corticotropin
(ACTH) do not interfere effectively.
The association constant (Ka) is determined from a
Scatchard plot (fig. 5). The bound (B)/free (F)-values
are plotted as a function of the bound ligand concentra-
tion. There is a linear range with K^- 1.8 · 109 1/mol
and another one at higher concentrations with
Ka2 = 8.2 - 107 1/mol.
Subcellular localization of pancreatic somatostatin
binding factor
In order to find out whether the binding factor is a cell
membrane, particle-bound substance (e.g. receptor) or
whether it is a soluble cytoplasmatic protein, fraction-
ating centrifugation was performed. Binding in super-
natants and pellets was determined after differential
centrifugations at 6QQg, 15 000 £, and 100 000 £. The
total binding increases with the ^-number and is highest
in the 100 000 ̂ -supernatant. The binding capacity of
the corresponding pellets remains constant. This suggests
that the binding factor is of cytoplasmic origin.
In another attempt to enrich the solubilized binding
factor in the cytosol fractions, the protein-solubilizing
agent, Triton X-100, was employed. Splenic lobe area
J. Clin. Chem. Clin. Biochem. / Vol. 19,1981 / No. 2
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Fig. 5. Scatchard plot of somatostatin binding.
Different concentrations of [ 12SI-Tyr1] somatostatin
from the G-25 chromatography (fraction 34, see fig. 1).
were incubated with cell-free extracts of the chicken pan-
creas "Pa" (10 Mg protein). The routine assay conditions
were performed, except that the incubation time was pro-
longed to 20 h. The ratio of bound [ 12SI-Tyr! 1 somato-
statin to free hormone is plotted as a function of specific
binding. Two association constants can be extrapolated:
Kal = 1.8 · 109 1/mol (or Kdl = 5.5 - 10'10 mol/1) and
Ka2 = 8.2 · 107 1/mol (orKd2 = 1.2 · 10'8 mol/1).
The specific radioactivity was calculated to be 6 MBq/
nmoL Each point gives the mean of duplicate values.
(P3) extract was treated with 10 ml/1 Triton X-100 during
homogenization.
Following a standard assay, radioactivity was measured
in the 15 000 £ fraction. The remaining bound radio-
active somatostatin is significantly higher (p < . 2)
in the untreated pellet compared with the Triton X-100-
treated pellet. In both cases, addition of cold somato-
statin before centrifugation causes an increase of binding
(fig.6a).
In contrast, when cold somatostatin is added to the
supernatants, suppression is achieved (fig. 6b). Maximal
binding capacity is about 0.206, and this is significantly
higher (p < 0.01). Suppression in the absence and pre-
sence of Triton X-100 is 0.076 and 0.032, respectively
(fig. 6b). This again suggests that the major binding
component is a soluble cytpsol molecule.
Characterization by gel-filtration
For further characterization, the cell-free extract of
"P3" was fractionated by gel filtration, and the specific
binding was measured in the fractions.
AcA 54 with a separation range of 5000-^70 000 was
used. The 280 nm absorption^diagram of the AcA 54-
chromatography and the corresponding binding values
are shown (fig. 7). In this experiment, incubation of
the 100 000 ̂ -supernatant with somatostatin was done
after column chromatography and concentrating of the
Fig. 6. Binding (B/T) of somatostatin with crude homogenate
of chicken pancreas "Pa" with and without Triton
X-100. Preparation of crude homogenate was carried
out as described in Materials and Methods. One sample
was homogenated in the presence of 10 ml/1 Triton
X-100. 20 ì\ (= 52 Mg protein) of an untreated (white
columns) and 20 ìÀ of the Triton X-100 sample (black
columns) were added to the routine binding assay
(Tab. 1).
To each second tube 16 ìÀ solution of cold cyclic somato-
statin was added. After 2 h incubation, samples were
centrifuged at 15 000^ for 10 min (4 °C) and radio-
activity was measured in the pellets (fig. 6a). The super-
natants were treated with charcoal, centrifuged, radio-
activity was measured and B/T-values were calculated,
(fig. 6b), S.D., n = 5. Suppression was achieved only in
the supernatants, and was highest in the samples without
Triton X-100.
fractions by freeze-drying. The results indicate elution
of the binding factor at Kav = 0.23. This suggests a mole-
cular weight of approximately 40 000 when compared
with the standard curve established with reference pro-
teins (fig. 7). Although the addition of Triton-X-100 had
been reported to have an influence on gel filtration
patterns (16) it was found that the Triton X-100-treated
samples have the same specific binding elution peak at
= 0.23.
Characterization by polyacrylamide disc gel electro-
phpresis
In order to elucidate electrophoretic properties of the
binding factor by a high resolution separation technique,
polyacrylamide disc gel electrophoresis was performed.
Typical electropherograms of radioactive somatostatin
and the binding incubates are presented in figure 8. Two
main peaks are located: the first at relative mobility
-0.6 and the second at = 0.36 (fig. 8,1). For comparison
a run with radioactive somatostatin (SRIF) is presented
in figure 8,2. Here a peak appears at = 0.36. This peak
can be totally extracted by treating the gels with tri-
chloroacetic acid (fig. 8,3 and 8,4). However, the radio-
activity at —0.6 is not extractable and indicates a
denatured stable binding complex (fig. 8,3).
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Fig. 7. Gel-filtration (Ultrogel AcA 54) of cell-free extract "P3" (100 000 #) and relative molecular mass (Mr) estimation.
13.6 mg protein (2 ml) were separated on an 1.6 X 61 cm column, 2 ml fractions were collected and freeze-dried. The void
volume appeared at fraction 20 and the "salt" peak at fraction 51. For further detail concerning gel-filtration see Materials
and Mathods.
Transmission at 280 nm.
Aliquots of several fractions were incubated with [^I-Tyr1 j somatostatin under standard conditions and the specific binding
(B/T) was calculated. v_ v
Determinations of relative molecular mass (MT) were carried out by comparison with K^-values* (K^ =——~) of cytochrome
Vf— V0
c (12 500), myoglobin (17 800), trypsin inhibitor from soybean (21 000), trypsin inhibitor from egg protein (28 000), oval-
bumin (45 000), and bovine serum albumin (68 000), as well as dextran blue 2000 (V0) and Na12*I (Vt) as reference materials.
*V = elution volume.
Figure 9 shows simultaneous runs of a disc electro-
phoresis with seven Ultrogel-AcA-54 fractions (the gel
filtration elution diagram is not shown here).
from the female rat. Schonbrunn & Tashjian (18)
described somatostatin receptor binding with cells of the
rat pituitary. In both cases, specificity of the binding
could be demonstrated. But the differences in the
reported thermodynamic data suggest differences in the
nature of somatostatin binding.
The highest radioactivity appears in a fraction correspond-
ing to Kav = 0.23 in gel filtration; this was shown in
experiments in which the specific binding was tested
after Ultrogel-fractionation (fig. 7). When the fraction cor- As the specific binding capacity which was measured in
responding to Kav = 0.2 is further separated by disc-
electrophoresis, the larger peaks at lower relative mobili-
ties suggest that the pancreatic binding factor in the
Kav = 0.2-fraction is still heterogeneous (fig. 10).
this work (ã- = 0.10/30 ì% protein) is relatively low com-
pared with the results of Ogawa et al. (8) (0.15-0.36/
The protein peaks at relative mobilities = 0.71 and
= 0.74 contain the pancreatic binding factor. This is
suggested by the fact that the unstained halves of the
gel slices bind labeled Tyr1-somatostatin at the same
relative mobilities as the above mentioned proteins
(Diel & Schneider, unpublished work).
Discussion
Specific binding between cyclic somatostatin and a
soluble binding factor has been detected in the chicken
pancreas. The highest concentrations of this binding
factor have been found in the splenic lobe area (P3).
This coincides with a preponderance of the somatostatin-
producing D-cells in this part of the organ (11; 17).
Recently, Ogawa et al. (8) found a specific somatostatin
binding protein while investigating several tissues, mainly
10 ^g protein) several possible interferring factors should
be recognized before further discussion of the binding
data.:
a) Somatostatin was radiolabeled at the Tyr1 ̂ residue of
the cyclic tetradecapeptide. This side chain of somato-
statin is not as important as other parts for the biological
activity of the hormone (19). It just may be essential for
the binding properties described here. Therefore, derivati-
sation and especially addition of iodine to the Tyr-residue
at the N-terminal may diminish the specific binding with
the pancreatic binding factor.
In addition, heterogeneity of [1?5I-Tyr*] somatostatin
should be taken into account. In recent work, this
phenomenon is demonstrated by isoelectric focusing
analysis (13), although purification of the labeled Tyr1-
somatostatin by G-25 Sephadex adsorption chromato-
graphy reveals only one main peak, which is retarded
(fig. i).
b) A paradoxical effect was observed when cold cyclic
somatostatin was added to the incubation medium. No
J. Clin. Chem. Clin. Biochem. / Vol. 19, 1981 /No. 2
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Fig. 8. Polyacrylamide disc gel electrophoresis of somatostatin-
binding complex from chicken pancreas "Pa". Disc
electiophoreses were performed simultaneously in a flat
gel apparatus (Desaga-Heidelberg, Germany) according
to the system of D*vw (15) pH 8.9-7.5%. Undiluted
homogenate of chicken pancreas "Pa" was incubated with
[1^5l-TyrMsomatostatin (3500 Bq) for l h at room tempe-
rature in 100 ìÀ and total volume tilled up to 1 ml with
assay buffer (tab. 1). 20 ìÀ samples were applied to the
spacer gel. Electrophoresis was carried out as described in
Materials and Methods.
a) Total incubation medium (binding complexes at relative
migration of 0.36 and 0.6)
b) I12sl-Tyf1lsomatostatin (relative migration = 0.36)
c) and d) were identical to a) and b) but treated with
125 g/1 trichloroacetic acid (after electrophoresis)
overnight at room temperature. The gels were sliced
in 2 mm pieces, arid radioactivity was measured.
Gels were stained overnight with Coomassie Brilliant Blue
R-250. One typical run is presented.
Slice number
Fig. 9. Polyacrylamide disc gel electrophoresis of seven fractions
of gel-filtered so ma to statin-binding complex of chicken
pancreas "Pa".
Gel filtration (AcA 54 RUltrogel) was performed as
described in figure 7. Disc electrophoresis is similar to
that demonstrated in figure 8. The freeze-dried fractions
of the gel filtration were redissolved in 50 ìÀ assay-buffer
(tab. 1) and incubated with 10 ìÀ [125I-Tyr1|somatostatin
(900 Bq) for l h at room temperature. 30 ìÀ aliquots
were applied. The unstained gels were sliced and radio-
activity was measured as described in Materials and
Methods. The fraction K& = 0.2 corresponds to the
maximal binding (peak) in figure 7.
displacement occurred, and even paradoxical increase
of binding was demonstrated in figure 6, where redis-
solved cell pellets were incubated with an excess of
cold cyclic somatostatin.
The possibility that somatostatin induces a positive co-
operation should be considered, but another explanation
is given by the fact that somatostatin polymerizes to a
high molecular compound, as observed in vitro (20) and
in vivo (21).
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Bound
radioactivity
I Start Distance migrated
Fig. 10. Poly aery lamide disc gel electro phoresis of the pancreatic
"P3" somatostatin binding factor after gel filtration
(Kw = 0.2).
The fraction at K^ = 0.2 of the gel filtration was
electrophorized and one half of the gel (longitudinal) was
treated with Coomassie Brilliant Blue R-250 and the
other one was incubated in 50 kBq [125I-Tyr1]somato-
statin (total volume 24 ml assay buffer for l h at room
temperature). Radioactivity and absorbance at 580 nm
were measured as described in Materials and Methods. The
arrows indicate the peaks which bind [125I-Tyr1] somato-
statin significantly (p < 0.01).
The exact nature of the self-polymerization is contro-
versial On one hand, Spiess & Vale (22) found that big
pancreatic somatostatin, as already supposed by Arimura
et al. (5), can be converted into the small form, which is
eluted with the tetradecapeptide by gel filtration. On the
other hand, Harris et al. (23), as well as Kronheim et al.
(24) and Conlon et al. (25) detected high molecular
somatostatin-like immunoreactivity (SLI) in plasma
(MT = 100 000) and suggested that somatostatin binds
to macromolecular compounds, the nature of which is
presently unknown.
c) Unspecific binding with e.g. bovine serum albumin
and ovalbumin (fig. 3) and cross-reactivity with other
ligands, as demonstrated in dose-response experiments
(fig. 4), may increase the interfering reactivities.
Weak cross-reactivity with glucagon, insulin and
corticotropin has been measured. The remarkably high
inhibition by the hypothalamic hormone luliberin is in
contrast to the weak effect of thyroliberin. Whether
this difference has biological relevance remains unknown.
Nevertheless, several of our results are in good agree-
ment with the work of Ogawa et al. (8) and Ogawa
et al. (26). These authors reported that Ca2"1" inhibits and
EDTA induces the binding. This corresponds to our own
observations (tab. 2) and recently was described by
Arimura et al. (27) for immunochemical binding.
The disulfide bridge of the somatostatin molecule is
likely to play a role in the interaction mechanism
(tab. 2). Ogawa et al. (8) suggest a two-step reaction, one
reversible event and another irreversible step, which in-
cludes the thiol-groups.
Experiments applying the reduced linear form of somato-
statin (two HS-groups) show a parallel but less sensitive
dose-response curve compared with the oxidized cyclic
coriformer (fig. 4). These experiments were performed
under nitrogen. Thus the reoxidation to cyclic somato-
statin is unlikely. As reduced glutathione (GSH) inhibits
the binding totally and reduces the S-S-bridge of cyclic
somatostatin spontaneously (experiments with NADP-
glutathione oxidoreductase EC 1.6.4.2, not presented)
it might be suggested that other arhirio acid residues are
involved in the binding mechanism.
The complexity of the binding mechanism is supported
by the results of the Scatchard plot (fig. 5). Two dissocia-
tion constants are calculated, KI = 5.5 · 10"10 mol/1,
which is similar to that found by Schonbrunn & Tashjian
(18) for receptor binding, and K2 = 1.2 · 1¼"8 mol/1,
which is similar to that calculated for the cytosol binding
protein presented by Ogawa et al. (8). In recent work
Leitner et al. (28) found Kt = 3.3 · 10"8 mol/1 and
K2 = 7.7 · 10"6 mol/1 fof binding at anterior pituitary
plasma membranes. For further characterization of the
pancreatic binding factor column ehromatography was
performed. Although this gel filtration technique is
similar to that which was carried out by Ogawa et al.
(8), there is a discrepancy between our own molecular
weight estimation (Mr = 40 000) and that reported by
these authors (Mr = 80 000). In our work, an Ultrogel
AcA 54 separation range 5000-70 000 and different
elution systems were used. Additional experiments
have to be done for a precise estimation of the mole-
cular weight.
In addition, fractional centrifugation and treatment
with solubilizer Triton X-100 were performed. Highest
values of specific binding were found in the 100 000 £
cytosol fractions, which were free from mitochondria
and membrane fragments (electron microscopy experi-
ments, supplied by Dr. H. Pickartz). Since it was impos-
sible to enrich the binding capacity by treatment of "P3"
extract with Triton X-100, it can be suggested that the
binding factor is a soluble and not a particle bound
(e.g. receptor) protein.
The disc electrophoresis experiments, which are pre-
sented in figures 8-10, indicate the existence of a
stable soluble somatostatin binding complex. The rela-
tive mobility is about 0.6. Ogawa et al. (26) reported
- 0.7.
As monomeric somatostatin possesses a high isoelectric
point, 9.5, Diel et al. (13), and 10-10.4, Conlon et al.
(25), it does not migrate into the polyacrylamide gel
unter the described circumstances. However, extract-
able radioactivity appears in a distinct peak,'relative
mobility = 0.36, when running [125I-Tyrl]somatostatin
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alone. This may be due to self-polymerization and self-
aggregation, and therefore, to a change of its physico-
chemical character (20).
Finally, the present data do not allow any conclusions
about the regulatory effects of the binding factor in
respect to the local functions between the different cells
of the pancreatic islets. Although a specific protein
binding assay for somatostatin could be developed using
the pancreatic binding factor (29), described here,
further work is necessary to elucidate details of the
specific binding of somatostatin, to classify whether
the binding factor acts as a carrier protein, and whether
specific receptors are located at the islet cells of the
pancreas.
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